These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21720745)

  • 1. Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.
    de Queiroz Crusoe E; Maiso P; Fernandez-Lazaro D; San-Segundo L; Garayoa M; Garcia-Gomez A; Gutierrez NC; Delgado M; Colado E; Martin-Sanchez J; Lee FY; Ocio EM
    Ann Hematol; 2012 Feb; 91(2):257-69. PubMed ID: 21720745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells.
    Dong Y; Liang C; Zhang B; Ma J; He X; Chen S; Zhang X; Chen W
    Cancer Lett; 2015 May; 361(1):137-46. PubMed ID: 25737303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib in the front-line treatment of multiple myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
    Bisping G; Wenning D; Kropff M; Gustavus D; Müller-Tidow C; Stelljes M; Munzert G; Hilberg F; Roth GJ; Stefanic M; Volpert S; Mesters RM; Berdel WE; Kienast J
    Clin Cancer Res; 2009 Jan; 15(2):520-31. PubMed ID: 19147757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
    Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
    Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
    Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
    Kuroda Y; Sakai A; Tsuyama N; Katayama Y; Munemasa S; Asaoku H; Okikawa Y; Nakaju N; Mizuno M; Ogawa K; Nishisaka T; Matsui H; Tanaka H; Kimura A
    Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
    Ocio EM; Vilanova D; Atadja P; Maiso P; Crusoe E; Fernández-Lázaro D; Garayoa M; San-Segundo L; Hernández-Iglesias T; de Alava E; Shao W; Yao YM; Pandiella A; San-Miguel JF
    Haematologica; 2010 May; 95(5):794-803. PubMed ID: 19951978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
    Raje N; Hideshima T; Mukherjee S; Raab M; Vallet S; Chhetri S; Cirstea D; Pozzi S; Mitsiades C; Rooney M; Kiziltepe T; Podar K; Okawa Y; Ikeda H; Carrasco R; Richardson PG; Chauhan D; Munshi NC; Sharma S; Parikh H; Chabner B; Scadden D; Anderson KC
    Leukemia; 2009 May; 23(5):961-70. PubMed ID: 19151776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
    Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
    Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
    Jagannath S; Dimopoulos MA; Lonial S
    Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
    Anderson KC
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
    Maiso P; Carvajal-Vergara X; Ocio EM; López-Pérez R; Mateo G; Gutiérrez N; Atadja P; Pandiella A; San Miguel JF
    Cancer Res; 2006 Jun; 66(11):5781-9. PubMed ID: 16740717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
    Chauhan D; Tian Z; Nicholson B; Kumar KG; Zhou B; Carrasco R; McDermott JL; Leach CA; Fulcinniti M; Kodrasov MP; Weinstock J; Kingsbury WD; Hideshima T; Shah PK; Minvielle S; Altun M; Kessler BM; Orlowski R; Richardson P; Munshi N; Anderson KC
    Cancer Cell; 2012 Sep; 22(3):345-58. PubMed ID: 22975377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
    Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P
    Oncology; 2006; 70(6):474-82. PubMed ID: 17283449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.